SlideShare a Scribd company logo
 
Disclaimer This presentation   may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at  www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform   them to future events or developments.
Operating Performance on Track Bayer achieved group financial targets in 2010,   sales up 13% (8%) to record €35.1bn, adj. EBITDA up 10% at €7.1bn, Core EPS up 15.1% at €4.19, proposed DPS of €1.50 Strong year at MaterialScience – HealthCare and CropScience below expectations,   adj. EBITDA margin at MaterialScience +750bpts, HealthCare lost 190bpts, CropScience drastically down by 420bpts Net income diminished by high special charges,   €1.7bn special charges mainly due to impairments/write-downs, litigation, reported EPS at €1.57 down 8% Strong operating cash flow – net financial debt reduced,   net cash flow up 7% to record €5.8bn, net debt lowered by €1.8bn to €7.9bn Good business momentum in Q4 2010, reported EBIT impacted by one-offs,   adj. sales up 8%, adj. EBITDA up 12%, Core EPS up 6% at €0.95, reported EBIT declined 86% due to €954m special charges Innovation pipeline with significant progress,  Xarelto Einstein DVT, Rocket AF data presented, submitted in EU, US Confidence for 2011: Core EPS expected to increase by about 10%
4th Quarter 2010 –  Strong Finish to a Solid Year Sales in € million % portfolio & currency adj. +8% EBITDA pre-special items in € million +12% Core EPS in € +6% Net Cash Flow in € million +10% Q4´09 Q4´10 9,012 7,872 Q4´09 Q4´10 1,689 1,513 Q4´09 Q4´10 0.95 0.90 Q4´09 Q4´10 1,941 1,766
4th Quarter 2010 – Reported EBIT Impacted by Special Items In € million -67 -135 -67 -135 Litigation -56 -180 -62 -199 Restructuring -56 -825 -32 Impairments -405 - Schering Brand -202 - Sagopilone / Bonefos -218 - Women’s Health & others EBITDA Effect EBIT Effect Q4 2010 Q4 2009 - 79 -85 Q4 2009 Others Q4 2010
4th Quarter 2010 – Reported Earnings Development In € million  -0.18 0.18 Earnings per share -86 51 366 EBIT 4 -237 -248 Non-operating results  -186 118 Pre-tax income  -145 153 Net income Δ% Q4 2009 Q4 2010
4th Quarter 2010 – Maintained Strong Business Momentum in Emerging Markets Latin America Eastern Europe Africa & Middle East Emerging Asia³ Emerging Economies Emerging Economies ¹ +19% Others² +4% USA -1% 10% 38% 32% 20% Western Europe +4% Q4 2010 Group sales by region Group €9,012m; +8% ~1,300 +24% ~1,200 +17% ~400 +11% ~500 +22% ¹  Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ²  Others = Japan, Australia, New Zealand, Canada ³  Emerging Asia = Asia minus Japan, Australia, New Zealand In € million,  Δ% yoy Fx adjusted
Fiscal 2010 – Record Net Cash Flow and Significantly Lower Debt Q4’10 Net Debt Development In € million -1.2 Q3´10 Q4´10 9.1 7.9 GCF oFCF 1,414 Invest- ments 524 1,417 Δ  % y-o-y +37% +11%  NCF 1,941 +10% +6% GCF oFCF 4,771 Invest- ments 1,514 4,259 Δ  % y-o-y +2% +12%  NCF 5,773 +7% -4% FY’10 -1.8 Q4´09 Q4´10 7.9 9.7 In € billion
4th Quarter 2010 – Top-Line Growth in All Segments ¹ Environmental Science/BioScience In € million, ( ) = Fx & portfolio adjusted Δ % 2010 2009 Δ % (adj.) 2010 2009 +79 266 149 +16 (+8) 1,367 1,177 Crop Protection -76 4 17 +29 (+20) 286 221 ES/BS ¹ +5 830 789 +7 (+2) 2,897 2,698 Pharma -16 308 365 +7 (+1) 1,571 1,466 Consumer Health adj. EBITDA Sales 297 270 1,138 203 166 1,154 2,016 1,398 4,164 MaterialScience CropScience HealthCare +63 +18 (+10) 1,653 +46 +28 (+22) 2,584 +7 (+1) -1 4,468
Pharma Pipeline – Significant Progress Achieved ,[object Object],Terminations ,[object Object],[object Object],Xarelto ,[object Object],[object Object],VEGF Trap-Eye ,[object Object],Approvals
4th Quarter 2010 – Top-Line Growth in All Segments ¹ Environmental Science/BioScience In € million, ( ) = Fx & portfolio adjusted Δ % 2010 2009 Δ % (adj.) 2010 2009 +79 266 149 +16 (+8) 1,367 1,177 Crop Protection -76 4 17 +29 (+20) 286 221 ES/BS ¹ +5 830 789 +7 (+2) 2,897 2,698 Pharma -16 308 365 +7 (+1) 1,571 1,466 Consumer Health adj. EBITDA Sales 297 270 1,138 203 166 1,154 2,016 1,398 4,164 MaterialScience CropScience HealthCare +63 +18 (+10) 1,653 +46 +28 (+22) 2,584 +7 (+1) -1 4,468
Fiscal 2010 – Group Performance vs. Targets ,[object Object],+15% € 4.19 ~10% Core EPS ,[object Object],-€1.8bn € 7.9bn reduce Net debt increase towards €7bn >5% Fx and portfolio adj. 2010 Outlook adj. EBITDA Sales ,[object Object],[object Object],+10% € 7.1bn +8% 2010 Δ ,[object Object],€ 35.1bn Comments 2010 actual
Fiscal 2010 – Subgroup Performance vs. Targets *EBITDA = pre-exceptional items ,[object Object],[object Object],[object Object],-14% 1,293 small increase EBITDA* MaterialScience +30% 10,154 +>10% Sales -1% 6,830 above market, i.e. 4% Sales +2% 16,913 market growth at least Sales -1% 4,405 increase EBITDA* substantial increase 2010 Outlook EBITDA* CropScience HealthCare in € million ,[object Object],[object Object],[object Object],+204% 1,356 adj.  Δ ,[object Object],[object Object],Comments 2010 actual
Outlook 2011 – Planning Assumptions  3.5 2.0 3.1 4.2 5.0 % 4 3 2 1 5.2 5 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],World Europe North America Latin America Asia/Pacific Africa/Middle East Change of GDP
Outlook 2011 – Planning Assumptions  Expected 2011 Global Market Development 5   %  Electro/electronic Positive development, high-single digit growth 31   %  Rx-pharma Mid-single digit growth, driven by emerging markets 10   %  OTC-pharma Demand improving, up to 4% growth 3   %  Diabetes care Globally 1%, US markets remain challenging 3   %  Animal Health Above average year, about 4% growth 18   %  Agrochemicals/ Seeds Positive development, mid-single digit growth ¹,  mainly volume driven 6   %  Automotive Further recovery, mid-single digit growth 5   %  Construction Economic pick-up expected, mid-single digit growth 5   %  Furniture/wood Ongoing recovery, low-single digit growth 14   %  Others Group sales break-down in % ¹assumes normal weather conditions
2011 Group Outlook Sales  Δ  Fx and portfolio adjusted, EBITDA pre-special items Outlook depends on specific planning assumptions as detailed in the 2010 annual report ~€5 ~10% +15% € 4.19 Core EPS ~€8bn improve towards €7.5bn +10% € 7.1bn adj. EBITDA Sales ~5% 4-6% +8% € 35.1bn Δ 2011E … 2012E 2010
Outlook 2011 – R&D and CapEx Budgets CropScience 0.7bn 1% MaterialScience 0.2bn HealthCare 2.1bn thereof  Pharma  1.8bn MaterialScience 0.6bn HealthCare 0.4bn Reconciliation 0.05bn 67% 24% 8% Reconciliation 0.2bn 26% 18% 44% 12% CropScience 0.3bn CapEx (PPE) 2011E:  ~€1.5bn R&D 2011E:  ~€3.1bn
2011 Guidance by Subgroup Outlook based on Fx and portfolio adj. sales and EBITDA pre-special items Outlook depends on specific planning assumptions as detailed in the 2010 annual report Mid-single digit increase of sales and overproportional growth of adj. EBITDA Q1 2011: Sales level with, adj. EBITDA above Q4’10 MaterialScience At least mid-single digit percent higher sales and overproportional growth of adj. EBITDA CropScience Consumer Health Pharma HealthCare Low- to mid-single digit increase of sales and improvement of adj. EBITDA-margin Mid-single digit growth of sales and adj. EBITDA Low- to mid-single digit increase of sales and small increase of adj. EBITDA
Science For A Better Life

More Related Content

What's hot

Q3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call PresentationQ3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call Presentation
Bayer
 
Q3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call PresentationQ3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call Presentation
Bayer
 
FY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call PresentationFY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call Presentation
Bayer
 
Q1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call PresentationQ1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call Presentation
Bayer
 
Q1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call PresentationQ1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call Presentation
Bayer
 
Q2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call PresentationQ2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call Presentation
Bayer
 
Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019
Bayer
 
FY/Q4 2021 Investor Conference Call Presentation
FY/Q4 2021 Investor Conference Call PresentationFY/Q4 2021 Investor Conference Call Presentation
FY/Q4 2021 Investor Conference Call Presentation
Bayer
 
FY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call PresentationFY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call Presentation
Bayer
 
FY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call PresentationFY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call Presentation
Bayer
 
FY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call PresentationFY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call Presentation
Bayer
 
Q2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call PresentationQ2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call Presentation
Bayer
 
Bayer AG Q3 2010 Investor Handout
Bayer AG Q3 2010 Investor HandoutBayer AG Q3 2010 Investor Handout
Bayer AG Q3 2010 Investor Handout
Bayer
 
Q1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call PresentationQ1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call Presentation
Bayer
 
Q2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call PresentationQ2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call Presentation
Bayer
 
Q3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call PresentationQ3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call Presentation
Bayer
 
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
Investor Conference Call Presentation:  Crop Science R&D Pipeline UpdateInvestor Conference Call Presentation:  Crop Science R&D Pipeline Update
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
Bayer
 
Resultados telefonica Primer Semestre
Resultados telefonica Primer SemestreResultados telefonica Primer Semestre
Resultados telefonica Primer Semestre
WEB FINANCIAL GROUP INTERNATIONAL SL
 
Invacare Corporation Fourth Quarter & Full year 2019 results
Invacare Corporation Fourth Quarter & Full year 2019 resultsInvacare Corporation Fourth Quarter & Full year 2019 results
Invacare Corporation Fourth Quarter & Full year 2019 results
rperezfont
 
Abengoa Third Quarter 2014 Earnings Presentation
Abengoa Third Quarter 2014 Earnings PresentationAbengoa Third Quarter 2014 Earnings Presentation
Abengoa Third Quarter 2014 Earnings Presentation
Abengoa
 

What's hot (20)

Q3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call PresentationQ3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call Presentation
 
Q3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call PresentationQ3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call Presentation
 
FY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call PresentationFY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call Presentation
 
Q1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call PresentationQ1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call Presentation
 
Q1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call PresentationQ1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call Presentation
 
Q2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call PresentationQ2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call Presentation
 
Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019
 
FY/Q4 2021 Investor Conference Call Presentation
FY/Q4 2021 Investor Conference Call PresentationFY/Q4 2021 Investor Conference Call Presentation
FY/Q4 2021 Investor Conference Call Presentation
 
FY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call PresentationFY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call Presentation
 
FY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call PresentationFY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call Presentation
 
FY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call PresentationFY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call Presentation
 
Q2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call PresentationQ2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call Presentation
 
Bayer AG Q3 2010 Investor Handout
Bayer AG Q3 2010 Investor HandoutBayer AG Q3 2010 Investor Handout
Bayer AG Q3 2010 Investor Handout
 
Q1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call PresentationQ1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call Presentation
 
Q2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call PresentationQ2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call Presentation
 
Q3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call PresentationQ3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call Presentation
 
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
Investor Conference Call Presentation:  Crop Science R&D Pipeline UpdateInvestor Conference Call Presentation:  Crop Science R&D Pipeline Update
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
 
Resultados telefonica Primer Semestre
Resultados telefonica Primer SemestreResultados telefonica Primer Semestre
Resultados telefonica Primer Semestre
 
Invacare Corporation Fourth Quarter & Full year 2019 results
Invacare Corporation Fourth Quarter & Full year 2019 resultsInvacare Corporation Fourth Quarter & Full year 2019 results
Invacare Corporation Fourth Quarter & Full year 2019 results
 
Abengoa Third Quarter 2014 Earnings Presentation
Abengoa Third Quarter 2014 Earnings PresentationAbengoa Third Quarter 2014 Earnings Presentation
Abengoa Third Quarter 2014 Earnings Presentation
 

Viewers also liked

Shire Business Group Brochure
Shire Business Group BrochureShire Business Group Brochure
Shire Business Group Brochure
Shire Business Group
 
Meet Management 2013 Investor Handout
Meet Management 2013 Investor HandoutMeet Management 2013 Investor Handout
Meet Management 2013 Investor Handout
Bayer
 
BILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus EserBILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus Eser
GBX Events
 
council_improvement_proposal Nambucca Shire
council_improvement_proposal Nambucca Shirecouncil_improvement_proposal Nambucca Shire
council_improvement_proposal Nambucca Shire
scott norman
 
FY/Q4 2014 Investor Conference Call Presentation Charts
FY/Q4 2014 Investor Conference Call Presentation ChartsFY/Q4 2014 Investor Conference Call Presentation Charts
FY/Q4 2014 Investor Conference Call Presentation Charts
Bayer
 
Meet management 2014-06-05_ny_investor_handout_web_slideshare
Meet management 2014-06-05_ny_investor_handout_web_slideshareMeet management 2014-06-05_ny_investor_handout_web_slideshare
Meet management 2014-06-05_ny_investor_handout_web_slideshare
Bayer
 
Biocon H1 FY 2012 Results Presentation
Biocon H1 FY 2012 Results PresentationBiocon H1 FY 2012 Results Presentation
Biocon H1 FY 2012 Results Presentation
Biocon
 
The Shire River Basin project basins as entry points
The Shire River Basin project basins as entry pointsThe Shire River Basin project basins as entry points
The Shire River Basin project basins as entry points
NAP Events
 
Sales and Distribution Management of Bayer Crop Science Limited
Sales and Distribution Management of Bayer Crop Science Limited Sales and Distribution Management of Bayer Crop Science Limited
Sales and Distribution Management of Bayer Crop Science Limited
Dr. Asokendu Samanta
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
cmcmarist8
 
Event Proposal - Bayer Dealer Conference 2013
Event Proposal - Bayer Dealer Conference 2013Event Proposal - Bayer Dealer Conference 2013
Event Proposal - Bayer Dealer Conference 2013
SonTranEventSpecialist
 
Suppy chain management of pharma
Suppy chain management of pharmaSuppy chain management of pharma
Suppy chain management of pharma
Ankit Kankane
 
Merck FY 2016
Merck FY 2016 Merck FY 2016
Merck FY 2016
Merck
 
The Top Skills That Can Get You Hired in 2017
The Top Skills That Can Get You Hired in 2017The Top Skills That Can Get You Hired in 2017
The Top Skills That Can Get You Hired in 2017
LinkedIn
 

Viewers also liked (14)

Shire Business Group Brochure
Shire Business Group BrochureShire Business Group Brochure
Shire Business Group Brochure
 
Meet Management 2013 Investor Handout
Meet Management 2013 Investor HandoutMeet Management 2013 Investor Handout
Meet Management 2013 Investor Handout
 
BILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus EserBILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus Eser
 
council_improvement_proposal Nambucca Shire
council_improvement_proposal Nambucca Shirecouncil_improvement_proposal Nambucca Shire
council_improvement_proposal Nambucca Shire
 
FY/Q4 2014 Investor Conference Call Presentation Charts
FY/Q4 2014 Investor Conference Call Presentation ChartsFY/Q4 2014 Investor Conference Call Presentation Charts
FY/Q4 2014 Investor Conference Call Presentation Charts
 
Meet management 2014-06-05_ny_investor_handout_web_slideshare
Meet management 2014-06-05_ny_investor_handout_web_slideshareMeet management 2014-06-05_ny_investor_handout_web_slideshare
Meet management 2014-06-05_ny_investor_handout_web_slideshare
 
Biocon H1 FY 2012 Results Presentation
Biocon H1 FY 2012 Results PresentationBiocon H1 FY 2012 Results Presentation
Biocon H1 FY 2012 Results Presentation
 
The Shire River Basin project basins as entry points
The Shire River Basin project basins as entry pointsThe Shire River Basin project basins as entry points
The Shire River Basin project basins as entry points
 
Sales and Distribution Management of Bayer Crop Science Limited
Sales and Distribution Management of Bayer Crop Science Limited Sales and Distribution Management of Bayer Crop Science Limited
Sales and Distribution Management of Bayer Crop Science Limited
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
Event Proposal - Bayer Dealer Conference 2013
Event Proposal - Bayer Dealer Conference 2013Event Proposal - Bayer Dealer Conference 2013
Event Proposal - Bayer Dealer Conference 2013
 
Suppy chain management of pharma
Suppy chain management of pharmaSuppy chain management of pharma
Suppy chain management of pharma
 
Merck FY 2016
Merck FY 2016 Merck FY 2016
Merck FY 2016
 
The Top Skills That Can Get You Hired in 2017
The Top Skills That Can Get You Hired in 2017The Top Skills That Can Get You Hired in 2017
The Top Skills That Can Get You Hired in 2017
 

Similar to FY Q4 2010 Investor Conference Call Presentation Charts

Q1 2011 Investor Conference Call Presentation Charts
Q1 2011 Investor Conference Call Presentation ChartsQ1 2011 Investor Conference Call Presentation Charts
Q1 2011 Investor Conference Call Presentation Charts
Bayer
 
FY results 2014 - press presentation
FY results 2014 - press presentationFY results 2014 - press presentation
FY results 2014 - press presentation
Ageas
 
Full year results 2013
Full year results 2013Full year results 2013
Full year results 2013
Ageas
 
Generali Group 2010 first half results
Generali Group 2010 first half resultsGenerali Group 2010 first half results
Generali Group 2010 first half results
Generali
 
3M results 2011
3M results 20113M results 2011
3M results 2011
Ageas
 
6M results 2012
6M results 20126M results 2012
6M results 2012
Ageas
 
PIRELLI FY'10 RESULTS
PIRELLI FY'10 RESULTSPIRELLI FY'10 RESULTS
Ageas Full Year 2015 Results (presentation)
Ageas Full Year 2015 Results (presentation)Ageas Full Year 2015 Results (presentation)
Ageas Full Year 2015 Results (presentation)
Ageas
 
Dt results q1_2012
Dt results q1_2012Dt results q1_2012
Dt results q1_2012
Deutsche Telekom
 
VFB 4 October 2014
VFB 4 October 2014 VFB 4 October 2014
VFB 4 October 2014
Ageas
 
FY results 2014
FY results 2014FY results 2014
FY results 2014
Ageas
 
Finance Avenue 2014
Finance Avenue 2014Finance Avenue 2014
Finance Avenue 2014
Ageas
 
3M results 2012
3M results 20123M results 2012
3M results 2012
Ageas
 
6M results 2011
6M results 20116M results 2011
6M results 2011
Ageas
 
DS Smith results 2010_11
DS Smith results 2010_11DS Smith results 2010_11
DS Smith results 2010_11
Eddy Priem
 
Kemira's January-June 2013 Interim Report
Kemira's January-June 2013 Interim ReportKemira's January-June 2013 Interim Report
Kemira's January-June 2013 Interim Report
Kemira Oyj
 
AT&S Quarterly Financial Report Q1 2018/19
AT&S Quarterly Financial Report Q1 2018/19AT&S Quarterly Financial Report Q1 2018/19
AT&S Quarterly Financial Report Q1 2018/19
AT&S_IR
 
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
Tricumen Ltd
 
Half-Year Financial Report 2018/19
Half-Year Financial Report 2018/19Half-Year Financial Report 2018/19
Half-Year Financial Report 2018/19
AT&S_IR
 
3M results 2010
3M results 2010 3M results 2010
3M results 2010
Ageas
 

Similar to FY Q4 2010 Investor Conference Call Presentation Charts (20)

Q1 2011 Investor Conference Call Presentation Charts
Q1 2011 Investor Conference Call Presentation ChartsQ1 2011 Investor Conference Call Presentation Charts
Q1 2011 Investor Conference Call Presentation Charts
 
FY results 2014 - press presentation
FY results 2014 - press presentationFY results 2014 - press presentation
FY results 2014 - press presentation
 
Full year results 2013
Full year results 2013Full year results 2013
Full year results 2013
 
Generali Group 2010 first half results
Generali Group 2010 first half resultsGenerali Group 2010 first half results
Generali Group 2010 first half results
 
3M results 2011
3M results 20113M results 2011
3M results 2011
 
6M results 2012
6M results 20126M results 2012
6M results 2012
 
PIRELLI FY'10 RESULTS
PIRELLI FY'10 RESULTSPIRELLI FY'10 RESULTS
PIRELLI FY'10 RESULTS
 
Ageas Full Year 2015 Results (presentation)
Ageas Full Year 2015 Results (presentation)Ageas Full Year 2015 Results (presentation)
Ageas Full Year 2015 Results (presentation)
 
Dt results q1_2012
Dt results q1_2012Dt results q1_2012
Dt results q1_2012
 
VFB 4 October 2014
VFB 4 October 2014 VFB 4 October 2014
VFB 4 October 2014
 
FY results 2014
FY results 2014FY results 2014
FY results 2014
 
Finance Avenue 2014
Finance Avenue 2014Finance Avenue 2014
Finance Avenue 2014
 
3M results 2012
3M results 20123M results 2012
3M results 2012
 
6M results 2011
6M results 20116M results 2011
6M results 2011
 
DS Smith results 2010_11
DS Smith results 2010_11DS Smith results 2010_11
DS Smith results 2010_11
 
Kemira's January-June 2013 Interim Report
Kemira's January-June 2013 Interim ReportKemira's January-June 2013 Interim Report
Kemira's January-June 2013 Interim Report
 
AT&S Quarterly Financial Report Q1 2018/19
AT&S Quarterly Financial Report Q1 2018/19AT&S Quarterly Financial Report Q1 2018/19
AT&S Quarterly Financial Report Q1 2018/19
 
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
Tricumen 4Q16/FY16 Wholesale Banking results review_open 270217
 
Half-Year Financial Report 2018/19
Half-Year Financial Report 2018/19Half-Year Financial Report 2018/19
Half-Year Financial Report 2018/19
 
3M results 2010
3M results 2010 3M results 2010
3M results 2010
 

More from Bayer

Q3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar PresentationQ3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar Presentation
Bayer
 
Q2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar PresentationQ2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar Presentation
Bayer
 
Q1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call PresentationQ1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call Presentation
Bayer
 
Q3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call PresentationQ3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call Presentation
Bayer
 
Q2 2022 Investor Conference Call Presentation
Q2 2022 Investor Conference Call PresentationQ2 2022 Investor Conference Call Presentation
Q2 2022 Investor Conference Call Presentation
Bayer
 
Q1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call PresentationQ1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call Presentation
Bayer
 
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
Bayer
 
Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018
Bayer
 
Q2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call PresentationQ2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call Presentation
Bayer
 
Q1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call PresentationQ1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call Presentation
Bayer
 

More from Bayer (10)

Q3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar PresentationQ3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar Presentation
 
Q2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar PresentationQ2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar Presentation
 
Q1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call PresentationQ1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call Presentation
 
Q3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call PresentationQ3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call Presentation
 
Q2 2022 Investor Conference Call Presentation
Q2 2022 Investor Conference Call PresentationQ2 2022 Investor Conference Call Presentation
Q2 2022 Investor Conference Call Presentation
 
Q1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call PresentationQ1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call Presentation
 
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
 
Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018
 
Q2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call PresentationQ2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call Presentation
 
Q1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call PresentationQ1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call Presentation
 

Recently uploaded

Collective Mining | Corporate Presentation - June 2024
Collective Mining  | Corporate Presentation - June 2024Collective Mining  | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
CollectiveMining1
 
Cleades robinson:The Diplomat is Blue
Cleades robinson:The Diplomat is BlueCleades robinson:The Diplomat is Blue
Cleades robinson:The Diplomat is Blue
Cleades Robinson
 
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
SOFTTECHHUB
 
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
f3wjr2q2
 
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
Osisko Gold Royalties Ltd
 
AGM Presentation Probe June 11 Final.pdf
AGM Presentation Probe June 11 Final.pdfAGM Presentation Probe June 11 Final.pdf
AGM Presentation Probe June 11 Final.pdf
Probe Gold
 
Methanex Investor Presentation - April 2024
Methanex Investor Presentation - April 2024Methanex Investor Presentation - April 2024
Methanex Investor Presentation - April 2024
Methanex Corporation
 
Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
CollectiveMining1
 
UnityNet World Environment Day Abraham Project 2024 Press Release
UnityNet World Environment Day Abraham Project 2024 Press ReleaseUnityNet World Environment Day Abraham Project 2024 Press Release
UnityNet World Environment Day Abraham Project 2024 Press Release
LHelferty
 
ppt-namibia-worldeconomy-standardbank.ppt
ppt-namibia-worldeconomy-standardbank.pptppt-namibia-worldeconomy-standardbank.ppt
ppt-namibia-worldeconomy-standardbank.ppt
TestOrg1
 
Cyberagent_For New Investors_EN_240424.pdf
Cyberagent_For New Investors_EN_240424.pdfCyberagent_For New Investors_EN_240424.pdf
Cyberagent_For New Investors_EN_240424.pdf
CyberAgent, Inc.
 
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptxUnderstanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
cosmo-soil
 
Corporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdfCorporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdf
Probe Gold
 
Mandalay Resouces June 2024 Investor Relations PPT
Mandalay Resouces June 2024 Investor Relations PPTMandalay Resouces June 2024 Investor Relations PPT
Mandalay Resouces June 2024 Investor Relations PPT
MandalayResources
 

Recently uploaded (14)

Collective Mining | Corporate Presentation - June 2024
Collective Mining  | Corporate Presentation - June 2024Collective Mining  | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
 
Cleades robinson:The Diplomat is Blue
Cleades robinson:The Diplomat is BlueCleades robinson:The Diplomat is Blue
Cleades robinson:The Diplomat is Blue
 
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
 
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
 
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, June 12, 2024
 
AGM Presentation Probe June 11 Final.pdf
AGM Presentation Probe June 11 Final.pdfAGM Presentation Probe June 11 Final.pdf
AGM Presentation Probe June 11 Final.pdf
 
Methanex Investor Presentation - April 2024
Methanex Investor Presentation - April 2024Methanex Investor Presentation - April 2024
Methanex Investor Presentation - April 2024
 
Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
 
UnityNet World Environment Day Abraham Project 2024 Press Release
UnityNet World Environment Day Abraham Project 2024 Press ReleaseUnityNet World Environment Day Abraham Project 2024 Press Release
UnityNet World Environment Day Abraham Project 2024 Press Release
 
ppt-namibia-worldeconomy-standardbank.ppt
ppt-namibia-worldeconomy-standardbank.pptppt-namibia-worldeconomy-standardbank.ppt
ppt-namibia-worldeconomy-standardbank.ppt
 
Cyberagent_For New Investors_EN_240424.pdf
Cyberagent_For New Investors_EN_240424.pdfCyberagent_For New Investors_EN_240424.pdf
Cyberagent_For New Investors_EN_240424.pdf
 
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptxUnderstanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
 
Corporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdfCorporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdf
 
Mandalay Resouces June 2024 Investor Relations PPT
Mandalay Resouces June 2024 Investor Relations PPTMandalay Resouces June 2024 Investor Relations PPT
Mandalay Resouces June 2024 Investor Relations PPT
 

FY Q4 2010 Investor Conference Call Presentation Charts

  • 1.  
  • 2. Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
  • 3. Operating Performance on Track Bayer achieved group financial targets in 2010, sales up 13% (8%) to record €35.1bn, adj. EBITDA up 10% at €7.1bn, Core EPS up 15.1% at €4.19, proposed DPS of €1.50 Strong year at MaterialScience – HealthCare and CropScience below expectations, adj. EBITDA margin at MaterialScience +750bpts, HealthCare lost 190bpts, CropScience drastically down by 420bpts Net income diminished by high special charges, €1.7bn special charges mainly due to impairments/write-downs, litigation, reported EPS at €1.57 down 8% Strong operating cash flow – net financial debt reduced, net cash flow up 7% to record €5.8bn, net debt lowered by €1.8bn to €7.9bn Good business momentum in Q4 2010, reported EBIT impacted by one-offs, adj. sales up 8%, adj. EBITDA up 12%, Core EPS up 6% at €0.95, reported EBIT declined 86% due to €954m special charges Innovation pipeline with significant progress, Xarelto Einstein DVT, Rocket AF data presented, submitted in EU, US Confidence for 2011: Core EPS expected to increase by about 10%
  • 4. 4th Quarter 2010 – Strong Finish to a Solid Year Sales in € million % portfolio & currency adj. +8% EBITDA pre-special items in € million +12% Core EPS in € +6% Net Cash Flow in € million +10% Q4´09 Q4´10 9,012 7,872 Q4´09 Q4´10 1,689 1,513 Q4´09 Q4´10 0.95 0.90 Q4´09 Q4´10 1,941 1,766
  • 5. 4th Quarter 2010 – Reported EBIT Impacted by Special Items In € million -67 -135 -67 -135 Litigation -56 -180 -62 -199 Restructuring -56 -825 -32 Impairments -405 - Schering Brand -202 - Sagopilone / Bonefos -218 - Women’s Health & others EBITDA Effect EBIT Effect Q4 2010 Q4 2009 - 79 -85 Q4 2009 Others Q4 2010
  • 6. 4th Quarter 2010 – Reported Earnings Development In € million  -0.18 0.18 Earnings per share -86 51 366 EBIT 4 -237 -248 Non-operating results  -186 118 Pre-tax income  -145 153 Net income Δ% Q4 2009 Q4 2010
  • 7. 4th Quarter 2010 – Maintained Strong Business Momentum in Emerging Markets Latin America Eastern Europe Africa & Middle East Emerging Asia³ Emerging Economies Emerging Economies ¹ +19% Others² +4% USA -1% 10% 38% 32% 20% Western Europe +4% Q4 2010 Group sales by region Group €9,012m; +8% ~1,300 +24% ~1,200 +17% ~400 +11% ~500 +22% ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia minus Japan, Australia, New Zealand In € million, Δ% yoy Fx adjusted
  • 8. Fiscal 2010 – Record Net Cash Flow and Significantly Lower Debt Q4’10 Net Debt Development In € million -1.2 Q3´10 Q4´10 9.1 7.9 GCF oFCF 1,414 Invest- ments 524 1,417 Δ % y-o-y +37% +11% NCF 1,941 +10% +6% GCF oFCF 4,771 Invest- ments 1,514 4,259 Δ % y-o-y +2% +12% NCF 5,773 +7% -4% FY’10 -1.8 Q4´09 Q4´10 7.9 9.7 In € billion
  • 9. 4th Quarter 2010 – Top-Line Growth in All Segments ¹ Environmental Science/BioScience In € million, ( ) = Fx & portfolio adjusted Δ % 2010 2009 Δ % (adj.) 2010 2009 +79 266 149 +16 (+8) 1,367 1,177 Crop Protection -76 4 17 +29 (+20) 286 221 ES/BS ¹ +5 830 789 +7 (+2) 2,897 2,698 Pharma -16 308 365 +7 (+1) 1,571 1,466 Consumer Health adj. EBITDA Sales 297 270 1,138 203 166 1,154 2,016 1,398 4,164 MaterialScience CropScience HealthCare +63 +18 (+10) 1,653 +46 +28 (+22) 2,584 +7 (+1) -1 4,468
  • 10.
  • 11. 4th Quarter 2010 – Top-Line Growth in All Segments ¹ Environmental Science/BioScience In € million, ( ) = Fx & portfolio adjusted Δ % 2010 2009 Δ % (adj.) 2010 2009 +79 266 149 +16 (+8) 1,367 1,177 Crop Protection -76 4 17 +29 (+20) 286 221 ES/BS ¹ +5 830 789 +7 (+2) 2,897 2,698 Pharma -16 308 365 +7 (+1) 1,571 1,466 Consumer Health adj. EBITDA Sales 297 270 1,138 203 166 1,154 2,016 1,398 4,164 MaterialScience CropScience HealthCare +63 +18 (+10) 1,653 +46 +28 (+22) 2,584 +7 (+1) -1 4,468
  • 12.
  • 13.
  • 14.
  • 15. Outlook 2011 – Planning Assumptions Expected 2011 Global Market Development 5 % Electro/electronic Positive development, high-single digit growth 31 % Rx-pharma Mid-single digit growth, driven by emerging markets 10 % OTC-pharma Demand improving, up to 4% growth 3 % Diabetes care Globally 1%, US markets remain challenging 3 % Animal Health Above average year, about 4% growth 18 % Agrochemicals/ Seeds Positive development, mid-single digit growth ¹, mainly volume driven 6 % Automotive Further recovery, mid-single digit growth 5 % Construction Economic pick-up expected, mid-single digit growth 5 % Furniture/wood Ongoing recovery, low-single digit growth 14 % Others Group sales break-down in % ¹assumes normal weather conditions
  • 16. 2011 Group Outlook Sales Δ Fx and portfolio adjusted, EBITDA pre-special items Outlook depends on specific planning assumptions as detailed in the 2010 annual report ~€5 ~10% +15% € 4.19 Core EPS ~€8bn improve towards €7.5bn +10% € 7.1bn adj. EBITDA Sales ~5% 4-6% +8% € 35.1bn Δ 2011E … 2012E 2010
  • 17. Outlook 2011 – R&D and CapEx Budgets CropScience 0.7bn 1% MaterialScience 0.2bn HealthCare 2.1bn thereof Pharma 1.8bn MaterialScience 0.6bn HealthCare 0.4bn Reconciliation 0.05bn 67% 24% 8% Reconciliation 0.2bn 26% 18% 44% 12% CropScience 0.3bn CapEx (PPE) 2011E: ~€1.5bn R&D 2011E: ~€3.1bn
  • 18. 2011 Guidance by Subgroup Outlook based on Fx and portfolio adj. sales and EBITDA pre-special items Outlook depends on specific planning assumptions as detailed in the 2010 annual report Mid-single digit increase of sales and overproportional growth of adj. EBITDA Q1 2011: Sales level with, adj. EBITDA above Q4’10 MaterialScience At least mid-single digit percent higher sales and overproportional growth of adj. EBITDA CropScience Consumer Health Pharma HealthCare Low- to mid-single digit increase of sales and improvement of adj. EBITDA-margin Mid-single digit growth of sales and adj. EBITDA Low- to mid-single digit increase of sales and small increase of adj. EBITDA
  • 19. Science For A Better Life